J
Jörg Wischhusen
Researcher at University of Würzburg
Publications - 68
Citations - 4631
Jörg Wischhusen is an academic researcher from University of Würzburg. The author has contributed to research in topics: Immune system & CD8. The author has an hindex of 26, co-authored 59 publications receiving 3925 citations.
Papers
More filters
Journal ArticleDOI
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Dagmar Beier,Peter Hau,Martin Proescholdt,Annette Lohmeier,Jörg Wischhusen,Peter J. Oefner,Ludwig Aigner,Alexander Brawanski,Ulrich Bogdahn,Christoph P. Beier +9 more
TL;DR: Together, the data provide first evidence that CD133(+) CSC maintain only a subset of primary glioblastomas, with apparent stem cell-like properties but distinct molecular profiles and growth characteristics in vitro and in vivo.
Journal ArticleDOI
A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape.
Heinz Wiendl,Meike Mitsdoerffer,Valeska Hofmeister,Jörg Wischhusen,Antje Bornemann,Richard Meyermann,Elisabeth H. Weiss,Arthur Melms,Michael Weller +8 more
TL;DR: It is concluded that the aberrant expression of HLA-G may contribute to immune escape in human glioblastoma.
Journal ArticleDOI
Temozolomide preferentially depletes cancer stem cells in glioblastoma.
Dagmar Beier,Stefanie Röhrl,Deepu R. Pillai,Stefanie Schwarz,Leoni A. Kunz-Schughart,Petra Leukel,Martin Proescholdt,Alexander Brawanski,Ulrich Bogdahn,Ariane Trampe-Kieslich,Bernd Giebel,Jörg Wischhusen,Guido Reifenberger,Peter Hau,Christoph P. Beier +14 more
TL;DR: The data strongly suggest that optimized temozolomide-based chemotherapeutic protocols might substantially improve the elimination of GBM stem cells and consequently prolong the survival of patients.
Journal ArticleDOI
Transcriptional Profiles of CD133+ and CD133− Glioblastoma-Derived Cancer Stem Cell Lines Suggest Different Cells of Origin
Claudio Lottaz,Dagmar Beier,Katharina Meyer,Praveen Kumar,Andreas Hermann,Johannes Schwarz,Markus Junker,Peter J. Oefner,Ulrich Bogdahn,Jörg Wischhusen,Rainer Spang,Alexander Storch,Christoph P. Beier,Christoph P. Beier +13 more
TL;DR: Comparing CSC lines with their putative cells of origin, the data suggest that the heterogeneous tumor entity GBM may derive from cells that have preserved or acquired properties of either fNSC or aNSC but lost the corresponding differentiation potential.
Journal ArticleDOI
Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint.
TL;DR: The hypothesis that GDF-15 acts as immune checkpoint and is thus an emerging target for cancer immunotherapy is supported, with particular emphasis on its immunomodulatory potential.